Logo-ddj
Submitted: 03 Jul 2022
Revision: 01 Sep 2022
Accepted: 03 Sep 2022
ePublished: 01 Oct 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Dis Diagn. 2022;11(4): 156-165.
doi: 10.34172/ddj.2022.30
  Abstract View: 271
  PDF Download: 218

Original Article

In Silico and In Vitro Analyses of PNPLA3 rs738409 C>G Polymorphism in Patients With Non-alcoholic Fatty Liver Disease

Fatemeh Safari 1 ORCID logo, Zeinab Imani-Saber 1 ORCID logo, Sima Mozafari 2 ORCID logo, Saeed Lotfi 3 ORCID logo, Nahid Einollahi 3* ORCID logo

1 Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran.
2 Department of Clinical Biochemistry, Tehran University of Medical Sciences, Tehran, Iran.
3 Department of Medical Laboratory Sciences, Tehran University of Medical Sciences, Tehran, Iran.
*Corresponding Author: Correspondence to Nahid Einollahi, Department of Medical Laboratory Sciences, Tehran University of Medical Sciences, Tehran, Iran. Tel: +982188982909, Email: , Email: einolahn@tums.ac.ir

Abstract

Background: The polymorphism associated with liver fat content, which is well-known as PNPLA3 rs738409 (Patatin-like phospholipase domain-containing protein 3), is one of the critical subjects widely investigated in the literature regarding the prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide. The present research aimed to study the bioinformatics investigations of this polymorphism together with the in vitro analyses among patients with NAFLD.

Materials and Methods: In this case-control study, after performing bioinformatics analysis, the laboratory examination was performed in several steps. Genomic DNA was extracted from the blood of 53 NAFLD patients and 107 subjects with normal liver ultrasounds. PNPLA3 rs738409 was genotyped by the polymerase chain reaction-restriction fragment length polymorphism method. The laboratory test results, including fasting blood sugar, triglyceride, cholesterol, high-density lipoprotein, low-density lipoprotein, alanine aminotransferase, and aspartate aminotransferase were collected from medical records. Finally, statistical analysis was performed using SPSS software, version 18.0.

Results: The frequency of the G allele was 56% and 36% among patients and in the control group, respectively. The frequency of genotypes was 35.8% and 47.7% (CC), 17% and 31.8% (CG), 47.2% and 20.6% (GG) in patients and control groups, respectively. The adjusted odds ratios for PNPLA3 rs738409 C>G were 3.0 (95% confidence interval [CI]: 1.28-6.98, P=.011) and 0.68 (95% CI: 0.25- 1.83, P = .44) for GG and CG genotypes, respectively.

Conclusion: The findings showed the association between the GG genotype and the presence of NAFLD. Furthermore, the bioinformatics findings suggested the probable risk of the disease incidence regarding the change of hydropathic characteristics resulting from the amino acid substitution.

First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 271

Your browser does not support the canvas element.


PDF Download: 218

Your browser does not support the canvas element.